Showing results (81-90 of 141) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2004
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancerWilliam L Dahut, James L Gulley, Philip M Arlen, et al.
Breast Cancer Research and Treatment|September 27, 2013
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinomaEleni Andreopoulou, Ivette S Vigoda, Vicente Valero, et al.
Nature Communications|October 17, 2020
Structure of inhibitor-bound mammalian complex IHannah R Bridges, Justin G Fedor, James N Blaza, et al.
The Journal of Urology|January 27, 2009
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablationWilliam D Figg, Maha H Hussain, James L Gulley, et al.
Investigational New Drugs|May 23, 2012
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerNilofer Azad, Arvind Dasari, John Arcaroli, et al.
Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2019
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic TransplantationKeith W Pratz, Michelle A Rudek, B Douglas Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2008
A phase II clinical trial of sorafenib in androgen-independent prostate cancerWilliam L Dahut, Charity Scripture, Edwin Posadas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemiasJudith E Karp, Antonino Passaniti, Ivana Gojo, et al.
Molecular Cancer Therapeutics|March 4, 2010
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohortMiguel Quintela-Fandino, Christophe Le Tourneau, Ignacio Duran, et al.
Pageof 15